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Abstract
Background: Nonmedical prescription opioid use has emerged as a major public health concern in recent years,
particularly in rural Appalachia. Little is known about the routes of administration (ROA) involved in nonmedical
prescription opioid use among rural and urban drug users. The purpose of this study was to describe rural-urban
differences in ROA for nonmedical prescription opioid use.
Methods: A purposive sample of 212 prescription drug users was recruited from a rural Appalachian county
(n = 101) and a major metropolitan area (n = 111) in Kentucky. Consenting participants were given an interviewer-
administered questionnaire examining sociodemographics, psychiatric disorders, and self-reported nonmedical use
and ROA (swallowing, snorting, injecting) for the following prescription drugs: buprenorphine, fentanyl,
hydrocodone, hydromorphone, methadone, morphine, OxyContin® and other oxycodone.
Results: Among urban participants, swallowing was the most common ROA, contrasting sharply with substance-
specific variation in ROA among rural participants. Among rural participants, snorting was the most frequent ROA
for hydrocodone, methadone, OxyContin®, and oxycodone, while injection was most common for hydromorphone
and morphine. In age-, gender-, and race-adjusted analyses, rural participants had significantly higher odds of
snorting hydrocodone, OxyContin®, and oxycodone than urban participants. Urban participants had significantly
higher odds of swallowing hydrocodone and oxycodone than did rural participants. Notably, among rural
participants, 67% of hydromorphone users and 63% of morphine users had injected the drugs.
Conclusions: Alternative ROA are common among rural drug users. This finding has implications for rural
substance abuse treatment and harm reduction, in which interventions should incorporate methods to prevent
and reduce route-specific health complications of drug use.
Background
There has been a meteoric rise in the rates of illicit pre-
scription opioid use and dependence in the US in recent
years [1,2]. According to the National Survey on Drug
Use and Health, prescription opioid nonmedical use has
quadrupled in the last 20 years [3] and, among new
initiates to illicit drug use, has surpassed marijuana use
[4]. Further, it appears that nonmedical prescription
opioid use is particularly problematic in rural areas
encompassing Appalachian Kentucky, Virginia and West
Virginia [5,6]. The health consequences of nonmedical
prescription opioid use can be severe; long-term use can
lead to physical dependence and addiction, and, at high-
doses, the drugs can cause severe respiratory distress
and death [7]. The motives for nonmedical use of pre-
scription drugs are various, but studies have identified
one of the most common to be individuals’ desire to
relieve physical pain [8]. Some evidence suggests that
chronic nonmalignant pain may be greater in rural areas
of the US [9], but without further research, proposed
links between the rural burden of nonmalignant pain
and nonmedical prescription opioid use are largely spec-
ulative. The growing burden of nonmedical prescription
drug use in America and its unique manifestations in
rural areas has warranted more research. For example,
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prescription opioid use have been examined using data
from signal detection systems [10], methadone mainte-
nance treatment enrollees [11], probationers [12], and
drug-related medical examiner cases [13]. However, to
our knowledge, there are no reports on rural-urban dif-
ferences in ways in which individuals are administering
prescription opioids.
Route of drug administration has important implica-
tions on users’ health outcomes, including risk of depen-
dence, susceptibility to infection, and experience of
route-specific health complications [14]. Injection drug
users, in particular, are at a heightened risk for HIV and
hepatitis C infection [15-18], drug dependence [19-21],
and overdose [22]. Individual-level risk factors related to
transitioning to injection drug use (IDU) from other
routes of administration include unemployment [23],
insecure income source [24], homelessness [23,25-27],
school dropout [24], and early-onset substance abuse
[28]. The extent of individuals’ previous substance use
[23,25] and frequency of substance use [26,27] have also
been identified as correlates. A number of social and eco-
logical factors also play a role in drug users’ risk for tran-
sitioning to injection. Perceived social support or
tolerance for injection [23,26], social pressure [29], and
geographic proximity to dealers [30] and other IDUs
[31], as well as having a friend [25], sex partner [23,32],
or family member who engages in IDU [24], are also
associated with transitioning to injection. Drug markets
[33], drug availability [30,34], and social norms surround-
ing typical routes of administration, collectively referred
to as “site ecology” c a na l s op l a yar o l e[ 2 7 ] .T e m p o r a l
trends in transitions to injection sometimes precipitated
by changes in drug availability have also been identified
[35,36]. Non-injection routes of administration are typi-
cally more expensive in terms of ‘bang per buck’, thus
transitioning to IDU can also entail economic motivation
[35]. Previous studies have shown that drug price [30]
and cost-effectiveness [27,29] can play a role in determin-
ing patterns in routes of administration as well.
Studies suggest that nonmedical prescription opioid
use can involve various routes of administration, the
choice of which can be influenced by demographic fac-
tors such as gender and age [37-41]. However, the influ-
ence of rurality on routes of administration for
nonmedical prescription opioid use has not been
explored. The purpose of this study was to describe
rural-urban differences in routes of administration for:
buprenorphine, fentanyl, hydrocodone, hydromorphone,
methadone, morphine, OxyContin®, and oxycodone.
Methods
A total of 212 participants entered the study in two
Kentucky counties, one a non-metropolitan Appalachian
county and the other in a metropolitan area of the
state’s Bluegrass region [42]. The rural county has been
designated by the Appalachian Regional Commission as
economically depressed [43]. Both counties are predomi-
nantly white (97.3% and 77.4%, respectively) [44].
Participants were recruited using snowball sampling,
which is most commonly used to access hidden popula-
tions such as drug users [45]. In the current study, partici-
pants who were initially recruited with flyers or by
community key informants who agreed to participate in the
study were asked to refer additional participants, who in
turn were asked to refer additional participants and so on.
Participants were eligible if they reported having used any
prescription opioid nonmedically in the prior 30 days and
OxyContin® at least once in the prior three years (either
medically or non-medically). The purposive sampling of
OxyContin® users is a product of the purpose of the overall
goal of the study, which was to compare outcomes of Oxy-
Contin® use among rural and urban drug users.
Data were collected between October 2008 and
August 2009. Interviewers were three research assistants
who resided in the target communities. After determin-
ing eligibility and obtaining informed consent, an inter-
viewer-administered questionnaire was utilized to gather
information on socio-demographic, medical, family/
social characteristics, and self-reported behaviors. The
MINI International Neuropsychiatric Interview, version
5.0 [46] was used to measure the following psychiatric
disorders: major depressive disorder (MDD), generalized
anxiety disorder (GAD), post-traumatic stress disorder
(PTSD) and antisocial personality disorder (ASPD).
Drug problem severity was examined using a composite
score from the Addiction Severity Index (ASI) [47]. For
the purposes of the current study, participants were also
asked to indicate lifetime and recent (past 30 day) use
of the following substances for the purposes of getting
high: buprenorphine (e.g., Subutex®, Suboxone®), fentanyl
patch, hydrocodone (e.g., Norco®, Vicodin®, Lorcet®, Lor-
tab®), hydromorphone (Dilaudid®), methadone tablets,
morphine (e.g., MSContin®, Kadian®, Avinza®), OxyCon-
tin® (tablets and generic), and other oxycodone (e.g.,
Tylox®, Percocet®, Percodan®). For each specific drug for
which participants reported lifetime use, they were
asked about the frequency of using the following routes
of administration: swallowing (including swallowing
whole and chewing to swallow), snorting, and injecting.
Participants were interviewed in locations such as a
library or other public places and were compensated
$50 for their time. The study was approved by the Uni-
versity of Kentucky Institutional Review Board.
Analysis
The dependent variable of interest was substance-specific
route of administration (i.e. for each substance, there
Young et al. Harm Reduction Journal 2010, 7:24
http://www.harmreductionjournal.com/content/7/1/24
Page 2 of 7were three dichotomous outcomes defined by lifetime
engagement in swallowing, injecting, and/or snorting as a
route of administration). Categorical and continuous
demographic characteristics of rural and urban drug
users were compared using chi-square tests and Mann-
Whitney U-tests, respectively. Logistic regression analysis
was used to examine differences between rural and urban
participants’ route of administration, adjusting for age,
gender, and race. The statistical software SPSS Version
17.0 (SPSS Inc., Chicago, IL) was used to conduct data
analysis.
Results
Description of the sample
Descriptive characteristics of the sample (n = 212) are
displayed in Table 1. Rural drug users comprised 47.6%
(n = 101) of the sample. The median age of all partici-
pants was 37 years and ranged from 20 to 69. The
majority of participants were men (54%) and 51% were
non-Hispanic white. The median number of years of
formal education completed was 12. Just under half
(49%) had been employed in the past 30 days and 20%
were receiving pension for disability. The median
monthly legal income was $665 and most participants
(59%) did not have health insurance. Just over 21% were
married or remarried, 34% were widowed, separated, or
divorced, and 45% had never been married. Rural parti-
cipants were significantly younger, had fewer years of
formal education, earned less income than urban partici-
pants, and had significantly higher drug problem severity
scores on the Addiction Severity Index. Significantly
more rural participants were non-Hispanic white, non-
religious, and married or remarried than were urban
participants.
Approximately half (46%) of participants had ever
enrolled in drug or alcohol treatment. Fifty percent of
t h es a m p l er e p o r t e dt h a tt h e yh a dac h r o n i cm e d i c a l
problem and 44% were regularly taking prescribed medi-
cation for a physical problem. Significantly more urban
participants were regularly taking prescribed medication
for a physical problem than rural participants. Approxi-
mately 35% of participants met the DSM-IV criteria for
major depressive disorder (MDD), 37% for generalized
anxiety disorder (GAD), 16% for post-traumatic stress
disorder (PTSD), and 30% for anti-social personality dis-
order (ASPD). Significantly more rural participants met
criteria for MDD than did urban participants (Table 1).
Drug Use and Route of Administration
Table 2 describes rural and urban nonmedical drug use
and the routes of drug administration for each of the
drugs. No urban participants reported lifetime use of
buprenorphine or of the fentanyl patch. Among rural
participants, however, 51% reported buprenorphine use
and 37% reported fentanyl use, both of which were most
commonly administered by swallowing. Interestingly,
Table 1 Comparison of demographic characteristics for rural (n = 101) and urban (n = 111) drug users
Descriptive characteristics Rural
n (%)
Urban
n (%)
Total
n (%)
P value
Male 57 (58.2) 56 (50.9) 113 (54.3) 0.294
White 96 (95.0) 11 (9.9) 107 (50.5) <0.001
Age - median (IQR) 33 (27 - 43) 42 (30 - 49) 37 (29 - 47) 0.004
Years in county - median (IQR) 31.0 (25 - 37) 30.5 (16.5 - 43) 31.0 (23 - 41) 0.467
Years of formal education - median (IQR) 12.0 (9 - 12) 12 (12 - 14) 12.0 (10 - 12.5) <0.001
Recent legal income*- median (IQR) $600 (300 - 800) $720.50 (468 - 1289) $665 (400 - 1020) 0.003
Employed in Past 30 Days 43 (42.6) 61 (55.0) 104 (49.1) 0.072
Receives Pension for Disability 21 (20.8) 21 (18.9) 42 (19.8) 0.733
Married/Remarried 29 (28.7) 16 (14.4) 45 (21.2) 0.011
Non-religious 64 (63.4) 30 (27.0) 94 (44.3) <0.001
Uninsured 57 (56.4) 68 (61.3) 125 (59.0) 0.488
Has Chronic Medical Problem 57 (56.4) 49 (44.1) 106 (50.0) 0.074
Prescribed Medication for Physical Problem 36 (35.6) 58 (52.3) 94 (44.3) 0.015
Ever Treated for Drug/Alcohol Problem 49 (48.5) 48 (43.2) 97 (45.8) 0.442
ASI Composite Drug Use Score - median (IQR) 0.26 (0.14 - 0.34) 0.08 (0.03 - 0.17) 0.16 (0.06 - 0.28) <0.001
Psychiatric characteristics
Major Depressive Disorder 47 (46.5) 28 (25.2) 75 (35.4) 0.001
Generalized Anxiety Disorder 41 (40.6) 38 (34.2) 79 (37.3) 0.339
Post-traumatic Stress Disorder 20 (19.8) 13 (11.7) 33 (15.6) 0.105
Anti-social Personality Disorder 32 (31.7) 31 (27.9) 63 (29.7) 0.550
IQR - Interquartile range, ASI - Addiction Severity Index [47].
*Income in past 30 days from employment, unemployment compensation, welfare, pension, benefits, social security, mate, family, friends, or child support.
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patch contents. Preferred route of administration varied
by substance and by rural/urban status. Among urban
participants, swallowing was the most common route of
administration across all substances. In age-, race-, and
gender-adjusted analyses, urban participants had signifi-
cantly higher odds of reporting swallowing hydrocodone
and oxycodone than did rural participants. Among rural
participants, the preferred route of administration varied
according to substance. For hydrocodone, methadone,
OxyContin®, and oxycodone, snorting was the most fre-
quent route of administration. Significantly more rural
participants reported snorting hydrocodone, OxyContin®,
and oxycodone than did urban participants, after adjust-
ment for age, race, and gender. For hydromorphone and
morphine use among rural drug users, injection was
most common. Notably, among rural participants, 67%
of hydromorphone users and 63% of morphine users
had administered the drugs by injection.
Discussion
Preferred route of administration varied by substance
and by rural/urban status. Among urban participants,
oral use (swallowing whole or chewing and swallowing)
was the most common route of administration. This
contrasted sharply with substance-specific variation in
routes of administration among rural participants. For
example, snorting was the most frequent route of
administration for hydrocodone, methadone, OxyCon-
tin®, and oxycodone, while injecting was most commonly
used for hydromorphone and morphine administration.
After adjustment for age, race, and gender, rural users
had significantly higher odds of snorting hydrocodone,
OxyContin®, and oxycodone compared to urban
participants.
The increased odds of rural participants to use alter-
native routes of administration warrant consideration.
Previous research has demonstrated that multiple routes
of administration are involved in nonmedical prescrip-
tion opioid use [40,41,48]. In fact, our finding on the
frequency of snorting OxyContin® compared to swallow-
ing and injecting is consistent with the findings of
another Kentucky study [39]. That study, conducted in a
clinic-based sample from central Kentucky, found that
methadone, morphine, and hydromorphone were being
administered through various alternative routes, includ-
ing snorting, chewing, and injecting [39].
Previous literature has posited that the decreased
availability of heroin in rural areas may contribute to
rural-urban differences in prescription opioid use
[11-13]; however, this trend is not apparent in this sam-
ple, as nearly twice as many rural participants reported
lifetime use of heroin than did urban participants (data
not shown). Rather, differences in the prevalence of
alternative routes of administration is likely to be more
intimately linked to differences in drug problem severity.
Previous substance use [23,25] and frequency of current
substance use [26,27] are known risk factors for transi-
tioning to injection from other routes of administration.
Scores from the Addiction Severity Index [47] indicate
that rural participants had much higher drug problem
severity than did urban participants, which may have
contributed to the rural/urban differences in route of
administration evident in this study.
The routes of administration for buprenorphine use
among rural participants in this study are consistent
with other studies [37,49-52]. For example, the relative
Table 2 Age-, gender-, and race-adjusted comparisons for
route of drug administration among rural (n = 101) and
urban (n = 111) drug users
Rural Urban Adjusted*
%% P-values
Buprenorphine (sublingual tablets) 50.5 0 —
Swallowing 31.7 0 —
Snorting 26.7 0 —
Injecting 3.0 0 —
Fentanyl (patch) 35.6 0 —
Swallowing 25.7 0 —
Snorting 1.0 0 —
Injecting 14.9 0 —
Hydrocodone (tablets) 90.1 91.9 0.408
Swallowing 68.3 91.9 0.046
Snorting 74.3 6.3 <0.001
Injecting 0 0 —
Hydromorphone (all formulations) 32.7 4.6 0.001
Swallowing 6.9 4.5 0.524
Snorting 5.9 0.9 0.472
Injecting 21.8 0 —
Methadone (tablets) 77.2 3.6 <0.001
Swallowing 27.7 3.6 0.083
Snorting 64.4 0 —
Injecting 1.0 0 —
Morphine (all formulations) 53.5 4.6 0.007
Swallowing 14.9 3.6 0.652
Snorting 17.8 0.9 0.547
Injecting 33.7 0 —
OxyContin®(generic/tablets) 86.1 23.6 0.002
Swallowing 25.7 22.5 0.442
Snorting 68.3 3.6 <0.001
Injecting 44.6 0 —
Other Oxycodone** (tablets) 83.2 50.0 0.374
Swallowing 31.7 47.7 0.026
Snorting 68.3 1.8 <0.001
Injecting 3.0 0 —
*p-values adjusting for age, race, and gender.
**Includes, for example, Tylox®, Percocet®, and Percodan®.
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injecting in this study is interesting with implications for
preventing diversion. Strategies intended to prevent
buprenorphine intravenous misuse, like Suboxone®, may
not prevent misuse by alternative routes of administra-
tion. The opiate antagonist naloxone contained within
Suboxone® “guards” against misuse by causing withdra-
wal symptoms in those who inject or snort it; however,
the data are conflicting [53].
The routes of fentanyl administration by rural study
participants are also noteworthy. Over 70% of rural fen-
tanyl users administered the drug orally. Oral adminis-
tration of fentanyl has been identified within other
populations [38,54-56]; however, these studies have gen-
erally found oral administration to be rare in compari-
son with other routes of administration. Oral fentanyl
administration can result in a wide range of concentra-
tions in the blood, depending on whether the substance
is retained in the oral cavity or swallowed [56,57].
Nevertheless, oral fentanyl administration can have fatal
consequences, as demonstrated by findings from post-
mortem studies of fentanyl-related deaths [55,56].
Injecting fentanyl, found among 42% of the fentanyl
users in this study, has also been reported in other
populations [55,58,59]. The frequency of fentanyl injec-
tion in this study is concerning given its implications for
toxicity and overdose. A fentanyl dose that is survivable
following transdermal administration may result in
death if administered intravenously [55]. Deaths due to
fentanyl overdose following injection can occur at low
blood concentrations (2.0 μg/L - 3.0 μg/L) [55,59-61].
These results are especially disconcerting given that
ambulance response times are significantly slower in
rural areas [62], which may increase the likelihood of
fatal overdose.
Perhaps most concerning about the high prevalence of
alternate routes of administration is the potential for
transmission of blood-borne infections such as HIV and
hepatitis B and C. While HIV and hepatitis C (HCV) in
particular are transmissible by injecting [63-65], it has
also been demonstrated that HCV can be transmitted by
sharing equipment used to snort drugs, such as straws
[65-67]. A seminal review by Strang and colleagues
(1998) discusses various health implications for route of
drug use, including nasal ulceration from snorting and
respiratory and thrombotic complications, abscesses,
and endocarditis from injecting [14]. The health
consequences of nonmedical prescription opioid use, as
delivered by any route of administration can be severe,
entailing potential for physical dependence and addic-
tion, severe respiratory distress, and fatal overdose [7].
Overdose risk, in particular, is compounded by the
route of administration [68]. Reports have noted that
this is especially problematic in OxyContin® use, which
was designed to be a slow-release formulation [69].
While this study broadens understanding of rural sub-
stance abuse and alternate routes of administration for
prescription opioids, it is not without limitations. The
data in this study are self-reported and are subject to
response bias. This study is also limited by sample size,
which prohibited making statistically meaningful rural-
urban comparisons for buprenorphine and fentanyl, as
well as statistically precise point estimates for certain
routes of administration of other substances. The rural-
urban comparisons were also complicated by the base-
line demographic differences between the two groups.
Race-, gender-, and age-adjusted analyses were used in
an attempt to isolate the influence of rurality on the
outcome of interest; however, a number of unmeasured
social, economic, and structural factors may have also
influenced the comparison. Also, given the influence of
ecological factors such as drug availability and drug
price on determining routes of administration [30], the
study would have been strengthened by an examination
of these characteristics in the rural and urban settings
involved.
Conclusions
This study offers valuable insight into the intricacies of
nonmedical rural opioid use in particular. These find-
ings suggest that alternative routes of administration are
common among rural drug users, a phenomenon which
is likely related to drug problem severity. This finding
has implications for rural substance abuse treatment as
well as prevention of transition from oral to other
routes of use such as snorting and/or injection. The pre-
sence of alternative routes of administration among
rural drug users also indicates a need for the implemen-
tation of harm reduction interventions within this
population.
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